|Articles|October 24, 2022
How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology, and Vaccines
Author(s)Emergent CDMO
Many CDMOs outsource their nanoparticle supply chain, but in house manufacturing of nanoparticles at CDMOs is anticipated to create new market opportunities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
3
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
4
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
5